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Summary
Background and aims: Currently, there is not a uniform consensus regarding the
number of criteria or speciﬁc cut-off values for the variety of tests that are used to
diagnose allergic bronchopulmonary aspergillosis (ABPA). Traditionally, an eosinophil
count >1000 cells/l is considered an important criterion in the diagnosis of ABPA.
The goal of this study was to delineate the signiﬁcance of the peripheral blood
eosinophil count in the diagnosis of ABPA, and the relationship between eosinophil
counts and lung function and immunological and radiological parameters.
Methods: This study was a retrospective analysis of the data from ABPA patients who
were managed in our chest clinic. Based on their eosinophil count, the patients were
classiﬁed into the following three categories: <500, 500—1000 and >1000 cells/l.
The spirometric, immunological and radiological characteristics were also assessed.
Results: We studied 108 males and 101 females with a combined mean (±SD)
age of 34.1± 12.5 years. The median (IQR) eosinophil count at diagnosis was
850 (510—1541) cells/l, and 60% of the patients had an eosinophil count of
<1000 cells/l. We found no relationship between eosinophil count and lung func-
tion using spirometry and other immunological parameters. The median eosinophil
count was higher in patients with an high resolution computed tomography (HRCT)
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chest ﬁnding of bronchiectasis (986 vs. 620, p < 0.001) vs. those without and in patients
with high-attenuation mucus (1200 vs. 800, p < 0.001) compared to those without
high-attenuation mucus.
Conclusions: A peripheral blood eosinophil count has limited utility in the diagnosis of
ABPA, and there is no relationship between eosinophil count and lung function or other
immunological parameters. The higher eosinophil count that we observed in patients
sis or high-attenuation mucus suggests that eosinophils are
ammatory activity in ABPA.
dulaziz University for Health Sciences. Published by Elsevier
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Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is
an immunological pulmonary disorder and occurs
in response to antigens that are released by the
ubiquitous fungus Aspergillus fumigatus, which col-
onizes the tracheobronchial tree [1]. The ABPA is a
common serious complication in the natural disease
course of patients with bronchial asthma and cystic
ﬁbrosis. Indeed, a recent systematic review esti-
mated that the prevalence of ABPA in asthma and
cystic ﬁbrosis is approximately 13 and 8%, respec-
tively [1,2]. ABPA was ﬁrst described in a report
by Hinson et al. in 1952 in the United Kingdom, in
which they described three cases of bronchopul-
monary aspergillosis [3]. The classic criteria that
were proposed by Rosenberg and Patterson are
commonly used in diagnosing ABPA [4,5]. However,
there is currently no uniform consensus with regard
to the number of criteria that are needed for diag-
nosis nor are there optimum disease-speciﬁc cut-off
values for the various tests that are employed in
establishing a diagnosis [6].
Depending upon the stage of the disease, the
immune-mediated damage in ABPA is reﬂected by
elevated levels of both total and A. fumigatus-
speciﬁc IgE and eosinophils. Eosinophils are
leukocytes that are derived from the bone marrow
[7,8]. In most reviews, a peripheral blood eosinophil
level above 1000 cells/l has been used as a crite-
rion for diagnosis of ABPA [1,9—11]. However, an
eosinophil count may be of limited diagnostic util-
ity, as many patients may not have an elevated
eosinophil count [12]. However, there is a paucity
of convincing published data that either support or
refute these claims. We observed that many of the
ABPA patients in our chest clinic had been screened
using an eosinophil count by their general/family
physicians. Many of these patients had counts that
were lower than 500—1000 cells/l, which pre-
cluded additional work-up of these patients. Using a
multivariate analysis, we demonstrated previously
t
(
f
(hat an eosinophil count does not reﬂect remission
n ABPA [13,14].
However, the relevance of eosinophil counts —
articularly, their role in the diagnosis of ABPA and
ts pathophysiological mechanisms — and their cor-
elation with other immunological and radiological
ndings, remain poorly understood. We hypoth-
sized that an elevated eosinophil count is not
elated to the others markers of severity in ABPA.
n the present study, we further delineated the role
f the eosinophil count in the diagnosis of ABPA and
he relationship of eosinophil levels with other diag-
ostic markers in a heterogeneous group of patients
ith ABPA.
aterials and methods
he study was a retrospective analysis of previously
ublished data and includes glucocorticoid-naïve
atients with ABPA that were diagnosed in the Chest
linic of Postgraduate Institute of Medical Educa-
ion and Research, Chandigarh from January 2002
hrough June 2008. The clinical characteristics and
utcomes of these patients have been described
reviously [13—16]. In our chest clinic, every
atient with asthma is screened for Aspergillus
ensitization using an intradermal skin test, and
atients who exhibit immediate cutaneous hyper-
eactivity are evaluated further by examining their
gE levels (both total and A. fumigatus-speciﬁc),
osinophil count, Aspergillus precipitins, and by
erforming high-resolution computed tomography
HRCT) of the chest. Patients who met both of
he following criteria were classiﬁed as ABPA
ases: a total IgE level >1000 IU/ml and an A.o have any two of the following four criteria:
a) the presence of serum precipitins against A.
umigatus; (b) radiographic pulmonary opacities
ﬁxed/transient); (c) an absolute eosinophil count
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tosinophil count in ABPA
1000 cells/l; and (d) central bronchiectasis that
as visible on HRCT [13—15,17]. All procedures,
ncluding the CT scans, were performed prior to
nitiating the glucocorticoid therapy and were per-
ormed within a 2—3-day period. The Institutional
thics Committee approved the study, and each
atient provided informed consent.
spergillus skin test
his test was performed using an A. fumigatus anti-
en that was prepared in the Department of Medical
ycology [18]. The test forearm was injected intra-
ermally with 0.2ml of the Aspergillus antigen
100 PNU/ml), and 0.2ml of phosphate-buffered
aline was injected in the other forearm to serve as
negative control. Reactions were classiﬁed as type
if wheal and erythema occurred within a minute,
eaked after 10—20min and resolved within 1—2h.
he antigen reaction in the arm skin needed to be
t least 8mm larger than the reaction in the con-
rol arm. Any residual subcutaneous edema after
h was classiﬁed as a type III reaction.
erum total IgE and A. fumigatus-speciﬁc
gE levels:
gE levels were measured using commercially avail-
ble kits that are based on the quantitative
nzyme-linked immunosorbent assay (Demeditec
iagnostics GmbH, Kiel, Germany) and ﬂuorescent
nzyme immunoassay (UniCap Systems; Pharmacia
Upjohn; Stockholm, Sweden).
igh-resolution CT (HRCT) of the chest:
CRT was performed using a 16-row, multiple-
etector CT scanner (LightSpeed Plus; GE Medical
ystems; Slough, UK) with a matrix size of
12× 512. The scans were obtained from the lung
pex to the lung base using a scan time of 3 s while
he patient was in the supine position at full end-
idal inspiration. Image acquisition was contiguous,
nd the images (1.25mm at 10-mm intervals) were
econstructed using a high-spatial-frequency algo-
ithm. The presence and extent of bronchiectasis
n the HRCT chest were categorized in accor-
ance with the criteria that were described by
eiff et al. [19]. Individual bronchopulmonary seg-
ents were identiﬁed based on their relationship
ith the major and minor ﬁssures and the appropri-
te lobar bronchi [20]. Bronchiectasis was classiﬁed
s ‘central’ when it was conﬁned to the medial
alf (the midway point between the hilum and
he chest wall) of the lung [21]. High-attenuation
a
s
u
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ucus (HAM) was considered to be present if the
ucus was visibly denser than the paraspinal skele-
al muscle [13,16,22].
. fumigatus precipitins
he A. fumigatus precipitins were detected using
he Ouchterlony gel diffusion technique according
o the method that was described by Longbottom
nd Pepys [23].
osinophil count
2-ml peripheral blood sample was collected into
n EDTA tube to perform an eosinophil count. The
umber of white blood cells (WBCs) was measured
sing an automated blood cell analyzer with a 5-
art differential (LH-750 or SF-3000). To measure
he eosinophils, a blood slide was prepared using
he Wright—Giemsa stain. An initial evaluation
t 10× magniﬁcation (total magniﬁcation 100×,
ncluding the eyepiece) provided an assessment of
he overall smear quality and the distribution of
he cells. A differential leukocyte count was per-
ormed at 100× (total 1000×) magniﬁcation. This
rocess involved counting and classifying 100 WBCs
nd recording the percentage of each WBC subtype.
e then multiplied the percentage by the total
eukocyte count to obtain the absolute eosinophil
ount.
Based on their absolute eosinophil counts, the
atients with ABPA were stratiﬁed into the fol-
owing three categories: <500, 500—1000, and
1000 cells/l. The relationship between these
ounts and the spirometric, immunological, and
adiological characteristics were assessed within
ach group.
pirometry
ach subject performed spirometry on a dry rolling-
eal spirometer (Spiroﬂow; PK Morgan Ltd.; Kent,
K). The values were measured according to the
merican Thoracic Society guidelines, and the
ighest measurements from among three techni-
ally acceptable and reproducible maneuvers were
btained at body temperature and pressure that
as saturated with water vapor [24]. The spirome-
er was calibrated frequently to ensure consistent
nd reliable performance. Age, gender, height and
pirometry data were recorded for each patient
sing our previously developed computer software
25].
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Table 1 Distribution of the eosinophil counts in 209
patients with allergic bronchopulmonary aspergillosis.
Category of eosinophil counta No. (%) of patients
Fewer than 500 50 (23.9)
500—1000 73 (34.9)
More than 1000 86 (41.1)
Quartile Range of eosinophil count
1st quartile (n = 52) 80—509
2nd quartile (n = 51) 512—847
3rd quartile (n = 54) 850—1520
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Statistical methods
The data are presented as the mean (SD), median
(IQR) or number (percentage). Differences with
a p-value of lower than 0.05 were considered
to be signiﬁcant. The differences between the
continuous variables were analyzed using the
Mann—Whitney U test or the Kruskal—Wallis test
(with Dwass—Steel—Critchlow—Fligner test for post
hoc analysis) where appropriate. The categori-
cal variables were compared using the Chi-square
test. Chi-square tests for more than 2× 2 rows or
columns were performed by extracting the 2× 2
table of interest from the original table and apply-
ing the Bonferroni adjustment for p-values. Linear
regression was performed to ascertain the strength
of the relationship between two quantitative vari-
ables. A scatter plot was initially constructed to
assess how closely the eosinophil counts approxi-
mated the serum IgE levels. The points were then
ﬁtted to a linear regression curve using the ordinary
least-squares method.
Results
This study comprised 108 males and 101 females
with a combined mean (SD) age of 34.1 (12.5)
years. The mean (SD) duration of asthma prior
to the diagnosis of ABPA was 9.4 (8.7) years.
Eighty-seven (41.6%) of the subjects had inappro-
priately received anti-tuberculous therapy in the
past. The baseline characteristics and outcome of
the patients were described previously [13—15].
One hundred and eighty-one (86.6%) of the subjects
were positive for Aspergillus precipitins. Central
bronchiectasis was present in 162 (77.5%) of the
patients, and the remaining patients were classi-
ﬁed as serological ABPA patients. HAM was present
in 41 (19.6%) of the patients based on the chest
HRCT.
Eosinophil counts at diagnosis
The median (IQR) eosinophil count was 850
(510—1541) cells/l, and the distribution of the
eosinophil counts is shown in Table 1. Approxi-
mately 60% of the patients had an eosinophil count
of fewer than 1000 cells/l.
Relationship between the eosinophil counts
and spirometry resultsForty-one (19.6%) of the patients exhibited normal
lung function on spirometry at diagnosis. There
was no signiﬁcant relationship between lung
w
i
<
e4th quartile (n = 52) 1562—14,124
a All eosinophil counts are given in cells/l.
unction abnormalities on spirometry and the level
f eosinophils (p = 0.63; Table 2). Bronchodilator
eversibility was present in 95 (45.5%) of the
atients and did not differ signiﬁcantly (p = 0.51)
etween the groups (Table 2).
elationship between the eosinophil counts
nd the immunological ﬁndings
he prevalence of Aspergillus precipitins was sim-
lar between the three categories of eosinophil
ounts (Table 2). However, in the post hoc analysis,
he median IgE levels were signiﬁcantly different
etween the categories (p = 0.012) with a trend
owards signiﬁcance in the patients whose counts
xceeded 1000 cells/l vs. those who had only
00—1000 cells/l (Table 2). The eosinophil counts
nd total IgE levels were converted to their corre-
ponding logarithmic values, and a linear regression
as applied to ascertain the signiﬁcance of the
esulting relationship. The linear regression yielded
n r2 value of 0.018 (with a variance of 2%), which
uggests that only 2% of the eosinophil counts can
e explained by the IgE level. This was conﬁrmed
y analyzing a scatter plot, which revealed a wide
istribution of the points along the intercept of the
tted line (Fig. 1). The A. fumigatus-speciﬁc IgE
evels were also not signiﬁcantly different between
he three groups, and this was conﬁrmed by linear
egression analysis (Fig. 2).
elationship between the eosinophil counts
nd the chest HRCT ﬁndings
he prevalence of central bronchiectasis and
AM were signiﬁcantly different between the
roups (p = 0.003 and p = 0.004, respectively),
ith both ﬁndings having a higher prevalence
n the >1000 cells/l group compared with the
500 cells/l group (Table 2). The median (range)
osinophil counts in the groups of patients with
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Table 2 Spirometric, immunological, and chest CT ﬁndings in the patients with different categories of eosinophil
counts.
Fewer than
500 cells/l
(n = 50)
500—1000 cells/l
(n = 73)
More than
1000 cells/l
(n = 86)
p value
Spirometry
Normal 7 (14) 17 (23.3) 17 (19.8) 0.63
Mild obstruction 14 (28) 22 (30.1) 18 (20.9)
Moderate obstruction 18 (36) 21 (28.8) 34 (39.5)
Severe obstruction 11 (22) 13 (17.8) 17 (19.8)
Bronchodilator reversibility 19 (38) 36 (49.3) 40 (46.5) 0.51
Immunological ﬁndings
Aspergillus precipitins 43 (86) 66 (90.4) 72 (83.7) 0.46
IgE levels (total), IU/ml;
median (IQR)
4345 (2475—7964) 4095 (2629.5—9193.5) 5769 (2926.3—10,965.3)a 0.012
A. fumigatus-speciﬁc IgE
levels, kUA/l; median (IQR)
2.19 (1.3—9.88) 4.7 (1.94—11.53) 4.8 (1.07—14.85) 0.3
HRCT ﬁndings
Central bronchiectasis 32 (64) 54 (74) 76 (88.4)a 0.003
No. of segments involved in
central bronchiectasis;
median (IQR)
6 (0—8) 5 (0—8) 6 (5—8) 0.46
High-attenuation mucus 3 (6) 13 (17.8) 25 (29.1)a 0.004
a The IgE levels, the occurrence of central bronchiectasis and the presence of high-attenuation mucus were signiﬁcantly higher
in patients with eosinophil counts >1000 cells/l compared to those with <500 cells/l. There was no signiﬁcant difference between
those with <500 cells/l and those with 500—1000 cells/l or between those with 500—1000 cells/l and those with eosinophil
counts >1000 cells/l.
Figure 1 Scatter plot showing the strength of the rela-
tionship between the eosinophil counts and the total IgE
levels. The individual eosinophil counts and IgE levels
were converted to their corresponding logarithmic val-
ues, and the regression line was ﬁt using the ordinary
least-squares method. The r2 value is 0.018 (with a vari-
ance of 2%), which suggests a weak relationship between
the two variables.
Figure 2 The relationship between the eosinophil
counts and the A. fumigatus-speciﬁc IgE levels. The scat-
ter plot presents the logarithmic transformations of the
individual eosinophil counts and IgE levels. The regres-
sion line was ﬁt using the ordinary least-squares method.
The r2 value is 0.001, which suggests a weak relationship
between the two variables.
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Figure 3 Box and whisker plot of the eosinophil counts
for the patients with and without bronchiectasis. The
box plot represents the 25th and 75th percentiles, the
internal horizontal line indicates the median and the T
Discussion
The results of this study suggest that the eosinophil
count has a limited role in the diagnosis of ABPA,
as 60% of the patients in our cohort had an
eosinophil count of fewer than 1000 cells/l, which
is the cutoff that is commonly used for diagnosis.
There was no relationship between the eosinophil
counts and lung function on spirometry, nor with
the other immunological parameters. Although the
prevalences of central bronchiectasis and high-
attenuation mucus were higher in the patients with
high eosinophil counts, the severity of bronchiecta-
sis was not correlated with the degree of peripheral
eosinophilia.
The Rosenberg—Patterson criteria are most
commonly used criteria in the diagnosis of ABPA
(Table 3) [4,5], and the presence of six of the
eight primary criteria provides a near-deﬁnitive
diagnosis. However, many of the criteria that
were proposed by Rosenberg and Patterson can
be considered redundant in the diagnosis of ABPA.
Table 3 Criteria that were used in the diagnosis of
allergic bronchopulmonary aspergillosis complicating
bronchial asthma.
Classic criteria [4,5]
Major criteria
• Immediate cutaneous hyper-reactivity to A.bars indicate the 5th and 95th percentiles. The eosinophil
counts were signiﬁcantly higher in the patients with
bronchiectasis (p = 0.001).
and without bronchiectasis were 620 (100—14,124)
and 986 (80—8200) cells/l, respectively, and
the eosinophil counts were signiﬁcantly higher
in the patients with bronchiectasis (p = 0.001,
Fig. 3). Similarly, the median eosinophil counts
were higher in the patients with HAM than in
the patients without HAM (800 vs. 1200 cells/l,
respectively, p = 0.0001; Fig. 4). However, the
severity of bronchiectasis (as assessed by the
number of involved bronchopulmonary segments)
was similar among the three groups.
Figure 4 Box and whisker plot of the eosinophil counts
for the patients with and without high-attenuation
mucus. The box plot represents the 25th and 75th per-
centiles, the internal horizontal line indicates the median
and the T-bars indicate the 5th and 95th percentiles. The
eosinophil counts were signiﬁcantly higher in the patients
with high-attenuation mucus (p = 0.0001).
fumigatus antigen
• Elevated serum total IgE levels (>1000 IU/ml)
• Elevated serum levels of A. fumigatus-speciﬁc IgG
and/or IgE
• Central bronchiectasis (CB) on HRCT of the chest
• Precipitating serum antibodies against A. fumigatus
• Fleeting pulmonary opacities on a chest radiograph
• Peripheral blood eosinophilia (>1000 cells/l)
Minor criteria
• Presence of Aspergillus in sputum
• Expectoration of brownish-black mucus plugs
• Delayed skin reaction to Aspergillus antigen (type III
reaction)
The presence of six out eight of the major criteria
provides a near-deﬁnitive diagnosis. The disease is
further classiﬁed as ABPA-S or ABPA-CB based on the
absence or presence, respectively, of CB.
Minimal diagnostic criteria [26,27]
• Immediate cutaneous hyper-reactivity to the A.
fumigatus antigen
• Elevated serum total IgE levels (>1000 IU/ml)
• Elevated A. fumigatus-speciﬁc IgG and/or IgE levels
• Central bronchiectasis on HRCT chest
The disease is further classiﬁed as ABPA-S or ABPA-CB
based on the absence or presence, respectively, of
CB.
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herefore, a set of minimal diagnostic criteria for
BPA has been proposed to facilitate an earlier
iagnosis of ABPA while using fewer diagnostic tests
Table 3) [26,27]. For example, serum precipitins
gainst A. fumigatus — although present in 69—90%
f ABPA patients [13,23,28—30] — are also present
n up to 10% of patients who have other pulmonary
isorders, including asthma [23,31,32]. Therefore,
his criterion represents supportive — but not
iagnostic — evidence of ABPA. A peripheral blood
osinophil count that is higher than 1000 cells/l
s also regarded as a primary criterion in the diag-
osis of ABPA. However, the results of the present
tudy clearly suggest that the eosinophil count has
imited utility in the diagnosis of ABPA and should
ot be used as a screening criterion. In our study,
pproximately 60% of the ABPA patients had an
osinophil count of lower than 1000 cells/l, and
pproximately 25% of the patients did not even
resent with peripheral blood eosinophilia (i.e.,
igher than 500 cells/l).
ABPA is characterized by an increased produc-
ion of eosinophils in the bone marrow, followed by
he accumulation of eosinophils in the tissues and
lood [33—38]. The inhaled spores and the subse-
uently released particulate A. fumigatus antigens
rigger a Th2 response in the lungs. This response
eads to release of IL-5, which then stimulates
rogenitor cells in the bone marrow to release
osinophils that feed back onto the site of inﬂam-
ation (i.e., the lung) [33,36,39]. Eosinophils are
redominantly tissue-dwelling cells, and their num-
ers in the tissues far exceed what is typically
ound in the blood [7]. Similarly, in ABPA patients,
he levels of eosinophils in the lung are far higher
han in the peripheral blood, although there seems
o be little correlation between these two fac-
ors [34,40]. This may explain the apparent lack
f peripheral eosinophilia in ABPA patients despite
tudies that have demonstrated high concentra-
ions of eosinophils in the pulmonary parenchyma.
e also did not ﬁnd any relationship between the
osinophil counts and other inﬂammatory markers,
ncluding the total and A. fumigatus-speciﬁc IgE
evels. The elevated IgE levels in ABPA patients are
ue to the A. fumigatus-induced production of IL-4.
L-5, however, is responsible for inducing the dif-
erentiation and recruitment of eosinophils in the
ung [41]. Thus, IgE and eosinophilia are regulated
ndependently [41], albeit by a common antigenic
ource (i.e., A. fumigatus).
The presence of large numbers of eosinophils in
he lungs of untreated ABPA patients suggests a pri-
ary proinﬂammatory role for eosinophils in ABPA.
osinophil cationic protein (ECP), a constituent of
osinophil granules, and eosinophil peroxidase have
a
n
t
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een implicated in epithelial shedding and mast
ell degranulation in patients with asthma [42].
n one study, eosinophils that were isolated from
atients with ABPA were stimulated in vitro with A.
umigatus allergens and exhibited higher eosinophil
eroxidase levels when compared with control
ells [43]. Similarly, another study found that the
nﬂammatory response in stable ABPA patients with
ronchiectasis was characterized by an increase
n the sputum eosinophil count and by evidence
f marked eosinophil degranulation with elevated
putum ECP levels [40]. Furthermore, a signiﬁcant
elationship has been reported between sputum
osinophil numbers and the extent of the disease
ased on HRCTs of the chest [40]. In our study, we
ound an association between the eosinophil levels
nd occurrences of central bronchiectasis and HAM.
his ﬁnding suggests that eosinophils are one of
he principal determinants of inﬂammatory activ-
ty in ABPA. However, the extent of bronchiectasis
id not correlate signiﬁcantly with the eosinophil
ount, possibly because we used only the peripheral
lood eosinophil count, which might not accurately
eﬂect ongoing pulmonary inﬂammation [34,40].
Finally, our study has several limitations. Most
mportantly, we did not perform an eosinophil count
n the sputum or bronchoalveolar lavage ﬂuid.
his might have been more deﬁnite, as eosinophils
ould have been recovered from the site of the
ngoing inﬂammation. Another limitation is the ret-
ospective nature of the study, especially given the
imited amount of data. Finally, we used a manual
ethod to count total eosinophils. Although manual
icroscopy is the current gold standard for WBC dif-
erential counts, it is time- and labor-intensive and
an be associated with large coefﬁcients of vari-
tion. Automated cell counters are the preferred
ethod for differential counts in most laboratories,
s they provide reliable clinical results in a shorter
ime and can be more reproducible than the man-
al approach [44]. Despite these limitations, one
trength of this study — in addition to the large
ample size — is the fact that all of the patients
ere glucocorticoid naïve. This provided us with an
ccurate estimation of the eosinophil count in ABPA
atients at the time of their diagnosis, as eosinophil
evels drop rapidly with corticosteroid therapy.
onclusions
n conclusion, the results of this study suggest that
n eosinophil count has limited utility for diag-
osing ABPA, as we found no correlation between
he eosinophil count and lung function or any
ther immunological parameters. The relationships
[[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
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between the peripheral blood eosinophil count and
central bronchiectasis and high-attenuation mucus
suggest that eosinophils are one of the primary
mediators of inﬂammation in ABPA.
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